Clinical trials: Hypertension, Pulmonary Artery
Hypertension, Pulmonary
Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension
This study will examine the effects of add-on sildenafil to bosentan monotherapy in patients with Pulmonary Arterial Hypertension.
- Trial name
- NCT00780728
- Testing
- Sildenafil
- Sponsor
- University Health Network, Toronto
Pulmonary Arterial Hypertension
Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585
Safety, tolerability, pharmacokinetics (PK), cardiac conduction and food effect study on single and multiple ascending doses of KAR5585 in healthy adults.
- Trial name
- NCT02746237
- Testing
- KAR5585 Capsules
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Karos Pharmaceuticals
Pulmonary Hypertension
Prospective Longitudinal Study of Patients With Idiopathic Pulmonary Arterial Hypertension, Family or Taking Anorectics
The objective of this clinical research is to analyze the survival of a cohort of patients newly diagnosed (incident cases) with idiopathic PAH, familial or associated with the use of anorectics (isolated pulmonary vascular…
- Trial name
- EFORT (NCT01185730)
- Testing
- Right Heart Catheterization
- Where
- France
- Volunteers
- 165 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atrial Fibrillation, Hypertension, Pulmonary
Safety Procedure Pulmonary Artery Denervation in Addition to Pulmonary Vein Isolation Combined With Ganglionated Plexi Ablation in Patients With Persistent Atrial Fibrillation and Pulmonary Hypertension
Some patients with a long history of AF develops PH "reactive" type with an increase in pulmonary vascular resistance due to vasoconstriction or structural changes of the vascular wall.
- Conditions
- Atrial Fibrillation, Hypertension, Pulmonary, Heart Diseases, Arrhythmias, Cardiac
- Trial name
- NCT02298244
- Testing
- PV isolation + GP Ablation, PV isolation + GP ablation + Pulmonary GP ablation
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Krasnoyarsk Regional Hospital
Pulmonary Arterial Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs.
- Trial name
- LIGHTRAY (NCT06664801)
- Testing
- Sotatercept, Background PAH Therapy
- Where
- 98 sites in United States, Argentina and 19 more
- Volunteers
- 164 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
The goal of this clinical trial is to evaluate safety and tolerability of preservative-free parenteral treprostinil in paediatric patients with PAH (PH Group 1) who are below 18 years of age.
- Trial name
- NCT06350032
- Testing
- preservative-free parenteral treprostinil
- Where
- 5 sites in Austria, France and 3 more
- Volunteers
- 20 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Pulmonary Arterial Hypertension (PAH), Quality of Life
Development and Validation of a Chinese Quality of Life Scale for Pulmonary Arterial Hypertension
This study aims to develop and validate a culturally appropriate, reliable, and clinically applicable patient-reported outcome (PRO) instrument to assess quality of life in patients with pulmonary arterial hypertension (PAH) in…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Quality of Life, Patients Reported Outcomes
- Trial name
- NCT07570615
- Testing
- Questionnaire Assessment
- Volunteers
- 300 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Idiopathic Pulmonary Arterial Hypertension
The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects
The purpose of this study is to Determine blood peptide levels and investigate any tissue gradients of apelin in patients with idiopathic pulmonary arterial hypertension and healthy volunteers.
- Trial name
- EXAP (NCT01590108)
- Testing
- (Pyr1)apelin-13, Saline
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)
COMPERA / COMPERA-KIDS
In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only provide part of the information needed for…
- Trial name
- COMPERA (NCT01347216)
- Where
- 7 sites in Belgium, Germany and 2 more
- Volunteers
- 14,000 people
- Sponsor
- Technische Universität Dresden
Pulmonary Arterial Hypertension
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
This is a multicenter, randomized (2:1 oral treprostinil: placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are currently receiving background dual therapy (ambrisentan…
- Trial name
- NCT02999906
- Testing
- Oral Treprostinil
- Sponsor
- United Therapeutics
Pulmonary Hypertension (PH) Due to Left Heart Disease
TReatment of Pulmonary Hypertension Group II Study
The objective of this study is to assess the safety and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation in group II PH patients through change in clinical parameters including hemodynamics…
- Trial name
- TROPHY-II (NCT03611270)
- Testing
- Pulmonary Denervation
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- SoniVie Inc.
Pulmonary Hypertension, Quality of Life
Quality of Life Questionnaire in Pulmonary Hypertension EMPHASIS-10: Brazilian Adaptation and Validation
Pulmonary hypertension (PH) is a severe and heterogeneous condition associated with poor prognosis and significant impairment in quality of life.
- Trial name
- EMPHASIS-10-BR (NCT07822997)
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Pulmonary Arterial Hypertension
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
This is a multi-center, randomized, double-blind, controlled, Phase 2 study to assess the safety, tolerability, and efficacy of pemziviptadil (PB1046) at the optimally titrated dose after 16 weeks of treatment.
- Trial name
- VIP (NCT03556020)
- Testing
- Pemziviptadil (PB1046)
- Where
- 26 sites in United States
- Volunteers
- 35 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Hypertension, Pulmonary Embolism (Diagnosis)
China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization
Right heart catheterization(RHC) plays a crucial role in the diagnosis and treatment of pulmonary vascular diseases(PVD). In China, the lack of equipment and technical expertise has historically limited the implementation of RHC…
- Conditions
- Pulmonary Hypertension, Pulmonary Embolism (Diagnosis), Pulmonary Arterial Hypertension, Right Heart Catheterization
- Trial name
- CHA-RHC (NCT06954727)
- Testing
- No intervention; Observational study
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- China-Japan Friendship Hospital
Pulmonary Arterial Hypertension
Apabetalone for Pulmonary Arterial Hypertension
Throughout the past twenty years, numerous specific pharmacologic agents targeting the endothelial dysfunction associated with PAH have emerged.
- Trial name
- APPROACH-2 (NCT04915300)
- Testing
- Apabetalone
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Laval University
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH).
- Trial name
- NCT07600723
- Testing
- Sotatercept, Background PAH Therapy
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Pediatric Pulmonary Hypertension
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better…
- Trial name
- MoD (NCT04039464)
- Testing
- Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Johns Hopkins University
Pulmonary Hypertension Group 1 and 4 According to Nice Classification
NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up
This observational study aims to chart patients which get their prostacyclin treatment via the subcutaneous LenusPro pump. How the surgical procedure is performed and the clinical follow-up of these patients.
- Trial name
- NCT01977014
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 40 people
- Sponsor
- NordicInfu Care AB
Pulmonary Arterial Hypertension, Cardiovascular Diseases
Effects of Different Types of Physical Training in Patients With Pulmonary Arterial Hypertension.
Although there has been some progress in pharmacological management of PAH, limited functional capacity and low survival still persist, but there is evidence that exercise training can be accomplished without adverse effects or…
- Conditions
- Pulmonary Arterial Hypertension, Cardiovascular Diseases, Respiratory Disease, Hypertension, Pulmonary
- Trial name
- PAH (NCT03476629)
- Testing
- Physical activity
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- University of Nove de Julho
Erectile Dysfunction, Pulmonary Arterial Hypertension
Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function
The study aims to investigate and compare the effect of TPN171H on subjects with mild and moderate hepatic impairment compared to healthy subjects.
- Trial name
- NCT05185011
- Testing
- TPN171H
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences